Shahram Kordasti

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium

Xingmin Feng, N. Daver, L. Adès, 2024, HemaSphere.

Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products

C. Montiel-Equihua, J. Colebrook, D. Choy, 2023, Molecular therapy oncolytics.

Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms

V. Santini, B. Peruzzi, U. Oelschlaegel, 2024, Leukemia.

Acute IL-6 exposure triggers canonical IL-6R signalling in hiPSC microglia, but not neural progenitor cells

A. Vernon, S. Kordasti, R. Duarte, 2022, bioRxiv.

Identification of an immune-related genes signature in lung adenocarcinoma to predict survival and response to immune checkpoint inhibitors.

Farideh Jafari-Raddani, Zeinab Davoodi-Moghaddam, Davood Bashash, 2024, Journal of the Egyptian National Cancer Institute.